Clinical trial
Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended…
NCT00202839 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00202839 |
|---|---|
| Title | Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED) |
| Official title | Comparison of the Sustained Response of Peg-Intron/Ribavirin Combination Therapy in Genotype 1-Infected Hepatitis C Patients for Non-extended Versus 24-week Extended Treatment After 24 Weeks Pilot Treatment in Taiwan |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Biological, Drug |
| Interventions | PegIntron (peginterferon alfa-2b, SCH 54031), Ribavirin |
| Enrollment | 160 |
| Start date | Mar 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Sep 20, 2005 |
| Last update posted | Apr 6, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: